Patents
Literature
2 results about "Dopamine transporter" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The dopamine transporter (also dopamine active transporter, DAT, SLC6A3) is a membrane-spanning protein that pumps the neurotransmitter dopamine out of the synaptic cleft back into cytosol. In the cytosol, other transporters sequester the dopamine into vesicles for storage and later release. Dopamine reuptake via DAT provides the primary mechanism through which dopamine is cleared from synapses, although there may be an exception in the prefrontal cortex, where evidence points to a possibly larger role of the norepinephrine transporter.
Targeting vehicles, compositions and uses thereof
A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.
Owner:CHINA MEDICAL UNIVERSITY(TW)
Deuterium-substituted FP-CIT linear precursor and method for preparing d6-[18f] FP-CIT by using same
PCT designated stageWO2026084437A1Isotope introduction to heterocyclic compoundsRadioactive preparation carriersRadioactive drugNeuro-degenerative disease
In the present invention, a deuterium-substituted FP-CIT linear precursor is developed in order to increase the linear stability of a precursor. When the deuterium-substituted FP-CIT linear precursor according to the present invention is dissolved in an organic solvent and stored, linearity is maintained well even at room temperature, and the same effect as a conventional radiopharmaceutical product [18F]FP-CIT is exhibited. In addition, D6-[18F]FP-CIT can be prepared simply and in a high yield, and thus can be effectively used as a starting material for the synthesis of D6-[18F]FP-CIT. Furthermore, a novel radiopharmaceutical product D6-[18F]FP-CIT enables visualization of dopamine transporter (DAT) distribution to be performed through improved image contrast, and has particularly high accuracy in diagnosing Parkinson's disease and related degenerative brain diseases, and thus can be effectively used.
![Deuterium-substituted FP-CIT linear precursor and method for preparing d6-[18f] FP-CIT by using same](https://images-eureka.patsnap.com/patent_img/302db1da-2e3a-48ef-b834-690169000c80/KR2025016192_23042026_pf_fp.png "Deuterium-substituted FP-CIT linear precursor and method for preparing d6-[18f] FP-CIT by using same")
Owner:THE ASAN FOUND +1